No Data
The U.S. bioterrorism law has undergone significant changes, the CRO concept has launched a major counterattack, and WuXi AppTec is excited!
Industry pessimistic expectations may improve.
How to break through the challenges in the development of innovative drugs? The industry suggests focusing on internationalization.
① The year 2024 will be the inaugural year of large-scale authorized trade, and going abroad has become an important direction for the development of local pharmaceutical companies; ② Chinese企业品牌, clinical trial capabilities, data presentation formats, and levels of international operation still need time and practical verification.
Mabpharm Limited (HKG:2181) Adds HK$392m in Market Cap and Insiders Have a 50% Stake in That Gain
MABPHARM-B: 2024 Interim Report
Express News | Mabpharm H1 Revenue RMB 108.5 Million
MABPHARM-B: INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2024
Some Mabpharm Limited (HKG:2181) Shareholders Look For Exit As Shares Take 41% Pounding
No Data
